{"id":910583,"date":"2025-11-17T07:11:55","date_gmt":"2025-11-17T12:11:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-announces-receipt-of-uspto-notice-of-allowance-for-key-patent-covering-glix1-for-treating-a-broad-range-of-cancer-types\/"},"modified":"2025-11-17T07:11:55","modified_gmt":"2025-11-17T12:11:55","slug":"biolinerx-announces-receipt-of-uspto-notice-of-allowance-for-key-patent-covering-glix1-for-treating-a-broad-range-of-cancer-types","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biolinerx-announces-receipt-of-uspto-notice-of-allowance-for-key-patent-covering-glix1-for-treating-a-broad-range-of-cancer-types\/","title":{"rendered":"BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Patent covers the use of GLIX1 for treating cancers in which\u00a0cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers)<\/i>\n <\/p>\n

\n Patent further broadens and strengthens GLIX1 patent protection until 2040, with a possible patent-term extension of up to five years<\/i>\n <\/p>\n

\n
\n TEL AVIV, Israel<\/span>
\n <\/span>, Nov. 17, 2025<\/span><\/span> \/PRNewswire\/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent, entitled, ‘Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies’ (Pat. Appl. Ser. No. 18\/602,969), which covers the use of GLIX1 for treating cancer types in which cytidine deaminase (CDA) is not over-expressed beyond a specific threshold. Corresponding patent applications are pending worldwide. The patent further broadens and strengthens GLIX1’s patent protection for the treatment of cancer until 2040, with a possible patent-term extension of up to five years.<\/p>\n

\n \"BioLineRx\n <\/div>\n

It is estimated that over 90% of all cancers do not overexpress CDA beyond the specific threshold, reflecting the importance of this additional intellectual property as BioLineRx expands development of GLIX1 beyond glioblastoma, its initial indication, into other cancer types, once safety and dosing in glioblastoma are established.<\/p>\n

“This Notice of Allowance from the USPTO is a critical addition to GLIX1’s intellectual property estate, as it protects our opportunity to evaluate this exciting molecule across the majority of cancers,” stated Philip Serlin<\/span>, Chief Executive Officer of BioLineRx. “As we prepare to initiate a first-in-human study of GLIX1 in patients with glioblastoma in the first quarter of 2026, we are in parallel advancing pre-clinical studies in other cancer models. We believe GLIX1, with its unique mechanism of action that targets the DNA damage response in cancer cells, has the potential to offer new hope to patients suffering from a broad range of difficult-to-treat cancers, and we are eager to commence clinical trials early next year.”<\/p>\n

GLIX1 is covered by a comprehensive portfolio of patents that are both issued and pending. In addition to the allowed U.S. patent referenced above and corresponding patents issued and pending worldwide, GLIX1 is covered by additional issued or pending patents, which broaden the coverage for its use in treating cancer as both monotherapy and in combination with established anti-cancer agents:<\/p>\n